Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Combination Trials Signal Next Wave of Treatment for CLL

October 9th 2018

Within the last decade, the FDA has approved 8 new agents for the treatment of patients with chronic lymphocytic leukemia.

Dr. Hill on Recent Advances in Treatment of CLL

October 9th 2018

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses recent advances in the treatment of patients with chronic lymphocytic leukemia.

Novel Agents and Approaches Continue to Advance Through CLL Pipeline

October 7th 2018

Mazyar Shadman, MD, MPH, discusses the evolution of therapy in CLL and how physicians are working to balance novel agents with additional modalities.

BTK Inhibitor Success Puts Focus on Resistance Mechanisms

October 2nd 2018

Less than 5 years after BTK inhibition was introduced in hematologic malignancies, the need for strategies to address primary and secondary mechanisms of resistance has emerged.

CLL Landscape Continues to Expand With Addition of Venetoclax

October 1st 2018

Javier A. Pinilla-Ibarz, MD, PhD, discusses updates in the treatment of patients with chronic lymphocytic leukemia.

Efficacy and Safety of Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies

September 30th 2018

B-cell malignancies are a heterogeneous subset of non-Hodgkin lymphomas in which treatment has remained essentially unchanged for the past 3 decades.

BTK Inhibitors: Real-World Insights on Patient Management and Therapy Selection

September 29th 2018

Nathan H. Fowler, MD, discusses the use of BTK inhibitors in B-cell malignancies.

The Changing Treatment Landscape in MCL and CLL: A Review of Standards of Care

September 28th 2018

Among the many new developments in B-cell lymphoma in recent years, the inhibition of Bruton tyrosine kinase represents a particularly notable achievement.

Dr. Shadman on the Future of Venetoclax in CLL

September 26th 2018

Mazyar Shadman, MD, MPH, assistant member, Fred Hutchinson Cancer Research Center, discusses the future of venetoclax (Venclexta) in the treatment of chronic lymphocytic leukemia (CLL).

Dr. Seymour on Shifting Standards of Care in CLL

September 25th 2018

Erlene Seymour, MD, an oncologist at Barbara Ann Karmanos Cancer Institute, Wayne State University, discusses shifting standards of care in chronic lymphocytic leukemia (CLL).

Dr. Flinn on the FDA Approval of Duvelisib in CLL and Follicular Lymphoma

September 25th 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of duvelisib (Copiktra) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or relapsed/refractory follicular lymphoma.

FDA Approves Duvelisib for CLL and Follicular Lymphoma

September 25th 2018

The FDA has approved duvelisib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed/refractory follicular lymphoma.

EU Panel Backs Venetoclax/Rituximab Combo in Relapsed/Refractory CLL

September 22nd 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use is supporting the approval of venetoclax in combination with rituximab for patients with chronic lymphocytic leukemia who have received at least 1 previous therapy.

CLL Paradigm Continues to Be Refined

September 20th 2018

Erlene Seymour, MD, discusses novel therapies as well as their potential applications in the treatment paradigm of chronic lymphocytic leukemia.

Dr. O'Brien Discusses Duvelisib in CLL

September 18th 2018

Susan M. O’Brien, MD, hematologist/oncologist at University of California, Irvine Health, discusses the promise of duvelisib in the treatment landscape of chronic lymphocytic leukemia.

Dr. Pinilla-Ibarz on the Impact of Venetoclax in CLL

September 13th 2018

Javier A. Pinilla-Ibarz, MD, PhD, senior member, Moffitt Cancer Center, discusses the impact of venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL).

FDA Updates Venetoclax CLL Label With MRD Data

September 12th 2018

The FDA has added minimal residual disease data from the phase III MURANO trial to the label for venetoclax for its approved use in combination with rituximab for previously-treated patients with chronic lymphocytic leukemia.

Dr. Brander on the Treatment of Relapsed/Refractory CLL

September 8th 2018

Danielle Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. Pinilla-Ibarz on the Role of Chemotherapy in CLL

September 7th 2018

Javier A. Pinilla-Ibarz, MD, PhD, senior member, Moffitt Cancer Center, discusses the role of chemotherapy in patients with chronic lymphocytic leukemia (CLL).

Dr. Dimopoulos Reflects on Ibrutinib Plus Rituximab in Waldenstrom Macroglobulinemia

August 27th 2018

Meletios Dimopoulos, MD, professor and chairman, Department of Clinical Therapeutics at the University of Athens School of Medicine, Athens, Greece, discusses the impact of the results from the iNNOVATE study of ibrutinib (Imbruvica) plus rituximab (Rituxan) in patients with Waldenström macroglobulinemia.